Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 195.35

-0.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (4295)	7/25/1997 8:37:00 PM
From: Henry Niman	of 32384

Andy, LGND announced the trial on March 20 and patients were to be on the drug for 120 days so patients enrolled then would have just completed their course of Targretin. However, I do not believe that the trial was blind. I think it was open label and each patient would serve as a control (glucose, insulin, and triglyceride levels would be monitored and compared to baseline values). The purpose of this small trial was to identify the most effective dose and provide preliminary data. The blood levels of the above compounds are hard numbers and do not require blinding. I'm not sure when the first and last patient was enrolled, but I would suspect that LGND has some preliminary data already (although the Rezulin data improved as the time on that drug approached 120 days). As far as insulin resistance is concerned, it is thought that Tragretin (and ALRT268) act via RXR activation and partnering with PPAR gamma (which then turns on genes that overcome insulin resistance). For all of the Rezulin data I have uploaded (except for FDA appoval), you can substitute Targretin for Rezulin and RXR for PPAR and re-read each article. Henry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next